REGISTRATION FOR SCHEDULED SHAREHOLDER INFORMATIONAL SESSION
OSLO, NORWAY (27 April 2017) – As previously announced, NattoPharma is pleased to invite investors, media and others to a presentation and business update to be held at the company’s corporate headquarter in Lilleakerveien 2B, Oslo, Norway on May 15th 2017.
The event will start with registration and coffee at 12:45, and the presentation will start at 13:00, followed by a Q&A session directly therafter.
If you would like to attend NattoPharmas presentation and business update, please register by email to CFO Kjetil Ramsøy, kjetil.ramsoy@nattopharma.com, within May 10th 2017.
The presentation will be held in English and will be published at approximately 12:30 the same day.
# # #
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and
international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com or menaq7.com.
For more information, please contact:
• Dan Rosenbaum, CEO
E-mail: Daniel.rosenbaum@nattopharma.com
• Kjetil Ramsoy, CFO
E-mail: kjetil.ramsoy@nattopharma.com
Tags: